You have requested access to member-only content.

Molecular pathology reimbursement still unclear

The AMA revised the molecular pathology codes in the CPT® Manual in 2012, but at that time CMS did not adopt the codes as it was still debating whether and how to change the reimbursement system for these services going forward. For CY 2013, CMS elected to recognize the codes, which meant it had to finalize how to pay for them. While CMS did not change pamyent for these services under the Clinical Laboratory Fee Schedule (CLFS) despite industry pressure, its change to the new codes means a change in the payments providers can expect this year and in the future.

This is an excerpt from member-only content. Please log in or become a member.

Not a member? Join now!

Revenue Cycle Advisor is the key to your organization's Medicare regulatory news and education. It combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule updates thoroughly.

For questions and support, please call customer service: 800-650-6787.